Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes
ABSTRACT Aims/Introduction This study aimed to evaluate and compare the effectiveness of oral semaglutide after adding to or switching from incretin‐related drugs by assessing the changes in HbA1c and body weight (BW) in participants with type 2 diabetes in clinical settings. Materials and Methods A...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Journal of Diabetes Investigation |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jdi.14391 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850154770920112128 |
|---|---|
| author | Junko Oya Mika Shimizu Ryo Kubota Rika Suda Tomoko Nagkagami |
| author_facet | Junko Oya Mika Shimizu Ryo Kubota Rika Suda Tomoko Nagkagami |
| author_sort | Junko Oya |
| collection | DOAJ |
| description | ABSTRACT Aims/Introduction This study aimed to evaluate and compare the effectiveness of oral semaglutide after adding to or switching from incretin‐related drugs by assessing the changes in HbA1c and body weight (BW) in participants with type 2 diabetes in clinical settings. Materials and Methods A total of 368 participants were divided into groups according to antidiabetic medications before oral semaglutide treatment; incretin‐related drug‐naïve (naïve), switching from dipeptidyl peptide‐4 inhibitors (DPP‐4i) or glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) groups. Adjusted mean changes in HbA1c and BW at 6 months after oral semaglutide administration were compared among the three groups. Similar analyses were performed in the GLP‐1 RAs group between GLP‐1RAs before switching. Results Mean change of HbA1c in DPP‐4i and GLP‐1 RA groups was −0.67% (95% confidence interval [CI]: −0.79 to −0.54) and −0.13% (95% CI: −0.40 to 0.15), respectively, which were significantly smaller than incretin‐related drug‐naïve group; −0.85% (95% CI: −1.08 to −0.62). Mean change in BW between the naïve and DPP‐4i groups had no differences; however, these changes were lower in the GLP‐1 RA group than in the naïve group. Mean change in HbA1c between pretreatment with GLP‐1 RAs had no differences; however, the mean change in BW in the dulaglutide group was significantly higher than that in the injectable semaglutide group. Conclusion Oral semaglutide reduced HbA1c levels and BW after adding or switching from other incretin‐related drugs in Japanese participants with type 2 diabetes. |
| format | Article |
| id | doaj-art-b83c2c057cb3463abf2fcf905cc8832f |
| institution | OA Journals |
| issn | 2040-1116 2040-1124 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Investigation |
| spelling | doaj-art-b83c2c057cb3463abf2fcf905cc8832f2025-08-20T02:25:12ZengWileyJournal of Diabetes Investigation2040-11162040-11242025-04-0116460861410.1111/jdi.14391Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetesJunko Oya0Mika Shimizu1Ryo Kubota2Rika Suda3Tomoko Nagkagami4Division of Diabetology and Metabolism, Department of Internal Medicine Tokyo Women's Medical University School of Medicine Tokyo JapanDivision of Diabetology and Metabolism, Department of Internal Medicine Tokyo Women's Medical University School of Medicine Tokyo JapanDivision of Diabetology and Metabolism, Department of Internal Medicine Tokyo Women's Medical University School of Medicine Tokyo JapanDivision of Diabetology and Metabolism, Department of Internal Medicine Tokyo Women's Medical University School of Medicine Tokyo JapanDivision of Diabetology and Metabolism, Department of Internal Medicine Tokyo Women's Medical University School of Medicine Tokyo JapanABSTRACT Aims/Introduction This study aimed to evaluate and compare the effectiveness of oral semaglutide after adding to or switching from incretin‐related drugs by assessing the changes in HbA1c and body weight (BW) in participants with type 2 diabetes in clinical settings. Materials and Methods A total of 368 participants were divided into groups according to antidiabetic medications before oral semaglutide treatment; incretin‐related drug‐naïve (naïve), switching from dipeptidyl peptide‐4 inhibitors (DPP‐4i) or glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) groups. Adjusted mean changes in HbA1c and BW at 6 months after oral semaglutide administration were compared among the three groups. Similar analyses were performed in the GLP‐1 RAs group between GLP‐1RAs before switching. Results Mean change of HbA1c in DPP‐4i and GLP‐1 RA groups was −0.67% (95% confidence interval [CI]: −0.79 to −0.54) and −0.13% (95% CI: −0.40 to 0.15), respectively, which were significantly smaller than incretin‐related drug‐naïve group; −0.85% (95% CI: −1.08 to −0.62). Mean change in BW between the naïve and DPP‐4i groups had no differences; however, these changes were lower in the GLP‐1 RA group than in the naïve group. Mean change in HbA1c between pretreatment with GLP‐1 RAs had no differences; however, the mean change in BW in the dulaglutide group was significantly higher than that in the injectable semaglutide group. Conclusion Oral semaglutide reduced HbA1c levels and BW after adding or switching from other incretin‐related drugs in Japanese participants with type 2 diabetes.https://doi.org/10.1111/jdi.14391Dipeptidyl peptidase‐4 inhibitorOral semaglutideReal‐world clinical setting |
| spellingShingle | Junko Oya Mika Shimizu Ryo Kubota Rika Suda Tomoko Nagkagami Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes Journal of Diabetes Investigation Dipeptidyl peptidase‐4 inhibitor Oral semaglutide Real‐world clinical setting |
| title | Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes |
| title_full | Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes |
| title_fullStr | Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes |
| title_full_unstemmed | Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes |
| title_short | Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes |
| title_sort | effectiveness for adding or switching from other incretin related drugs to oral semaglutide in type 2 diabetes |
| topic | Dipeptidyl peptidase‐4 inhibitor Oral semaglutide Real‐world clinical setting |
| url | https://doi.org/10.1111/jdi.14391 |
| work_keys_str_mv | AT junkooya effectivenessforaddingorswitchingfromotherincretinrelateddrugstooralsemaglutideintype2diabetes AT mikashimizu effectivenessforaddingorswitchingfromotherincretinrelateddrugstooralsemaglutideintype2diabetes AT ryokubota effectivenessforaddingorswitchingfromotherincretinrelateddrugstooralsemaglutideintype2diabetes AT rikasuda effectivenessforaddingorswitchingfromotherincretinrelateddrugstooralsemaglutideintype2diabetes AT tomokonagkagami effectivenessforaddingorswitchingfromotherincretinrelateddrugstooralsemaglutideintype2diabetes |